NCT06518382 2026-04-15
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
IRCCS Ospedale San Raffaele
Recruiting
Clinical Trials
27 trialsNCT07470203 2026-03-13
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT05253911 2025-12-04
TRACE
iOMEDICO AG
Completed
NCT03738553 2025-10-29
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
Active not recruiting
NCT01722890 2025-07-08
CharactHer. ICORG 12-09, V3
Cancer Trials Ireland
Terminated
NCT06833268 2025-07-08
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
Daiichi Sankyo
Completed
NCT07019272 2025-06-13
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Hebei Medical University Fourth Hospital
Not yet recruiting
NCT06754059 2025-01-01
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
Fujian Medical University Union Hospital
Recruiting
NCT06722599 2024-12-09
LRNacHER2
Peking University People's Hospital
Recruiting
NCT06722612 2024-12-09
TaxCbHER2
Peking University People's Hospital
Recruiting
NCT06711055 2024-12-02
TaxHER
Peking University People's Hospital
Recruiting
NCT06711068 2024-12-02
TaxDHER2
Peking University People's Hospital
Recruiting
NCT06700369 2024-11-25
NacHER2
Peking University People's Hospital
Recruiting
NCT06693024 2024-11-20
NeraHER2
Peking University People's Hospital
Recruiting
NCT06693037 2024-11-20
nonPHER
Peking University People's Hospital
Recruiting
NCT05149014 2024-09-26
Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer
Daiichi Sankyo France
Completed
NCT05433753 2024-03-25
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
National Cancer Center, Japan
Recruiting
NCT05458401 2024-03-15
EUROPA T-DXd
Daiichi Sankyo
Completed
NCT06161922 2023-12-08
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Fudan University
Unknown
NCT05769751 2023-08-16
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
Daiichi Sankyo
Completed
NCT04288141 2022-11-14
HERdi PREDICT
King's College London
Unknown
NCT05561686 2022-09-30
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Hunan Cancer Hospital
Unknown
NCT04638725 2022-08-03
SIGHER
Institut de cancérologie Strasbourg Europe
Recruiting
NCT04756921 2021-02-16
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Fudan University
Completed
NCT04158505 2020-04-24
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
ChineseAMS
Unknown
NCT04276337 2020-02-19
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Samsung Medical Center
Unknown
NCT04011085 2019-07-08
Tw HER2 Positive Breast Cancer Productivity & Utility Study
Taiwan Epidemiology Association
Unknown